AbbVie and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform,announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology. The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates.
"We are excited about the purpose-built AI capabilities Iambic is bringing to our Discovery scientists," said Nicholas Donoghoe, M.D., executive vice president and chief business and strategy officer, AbbVie. "We believe AI will be a powerful catalyst for scientific innovation across AbbVie. By equipping our teams with fit-for-purpose AI solutions, we can accelerate discovery, expand what is possible in R&D and significantly advance our commitment to making a remarkable impact for patients."
"Combining Iambic's platform with the drug-hunting expertise of AbbVie scientists can help us make more precise decisions about the molecules we pursue," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success, ultimately to deliver breakthrough medicines for patients sooner."